Paratek Pharmicals（纳斯达克股票代码：PRTK）股价突破200日移动平均线2.25美元

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.25 and traded as high as $2.63. Paratek Pharmaceuticals shares last traded at $2.57, with a volume of 367,602 shares traded.

Analyst Upgrades and Downgrades

PRTK has been the subject of a number of recent analyst reports. HC Wainwright decreased their target price on Paratek Pharmaceuticals from $20.00 to $10.00 in a research report on Monday, March 20th. StockNews.com assumed coverage on Paratek Pharmaceuticals in a research report on Thursday, March 16th. They issued a "hold" rating on the stock.

Paratek Pharmaceuticals Stock Down 3.0 %

The firm has a 50 day moving average of $1.99 and a 200-day moving average of $2.25. The company has a market cap of $147.16 million, a P/E ratio of -2.18 and a beta of 1.60.

Insider Activity

In other Paratek Pharmaceuticals news, major shareholder James D. Dondero purchased 105,137 shares of the firm's stock in a transaction on Monday, March 20th. The stock was bought at an average cost of $1.40 per share, for a total transaction of $147,191.80. Following the completion of the purchase, the insider now owns 2,239,770 shares in the company, valued at approximately $3,135,678. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder James D. Dondero bought 105,137 shares of the stock in a transaction dated Monday, March 20th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $147,191.80. Following the completion of the purchase, the insider now directly owns 2,239,770 shares of the company's stock, valued at $3,135,678. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder James D. Dondero acquired 234,863 shares of the firm's stock in a transaction on Friday, March 17th. The stock was purchased at an average price of $1.50 per share, with a total value of $352,294.50. Following the transaction, the insider now owns 2,134,663 shares of the company's stock, valued at approximately $3,201,994.50. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 446,000 shares of company stock worth $687,106. 8.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PRTK. Baird Financial Group Inc. increased its holdings in shares of Paratek Pharmaceuticals by 12.8% during the 3rd quarter. Baird Financial Group Inc. now owns 49,070 shares of the specialty pharmaceutical company's stock worth $126,000 after buying an additional 5,570 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Paratek Pharmaceuticals by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 259,942 shares of the specialty pharmaceutical company's stock valued at $772,000 after purchasing an additional 5,629 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Paratek Pharmaceuticals by 28.9% during the 1st quarter. JPMorgan Chase & Co. now owns 28,946 shares of the specialty pharmaceutical company's stock worth $86,000 after buying an additional 6,497 shares during the period. Prospera Financial Services Inc increased its position in shares of Paratek Pharmaceuticals by 156.8% in the 3rd quarter. Prospera Financial Services Inc now owns 11,465 shares of the specialty pharmaceutical company's stock valued at $29,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Paratek Pharmaceuticals by 5.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 129,672 shares of the specialty pharmaceutical company's stock worth $386,000 after purchasing an additional 7,019 shares in the last quarter. 41.90% of the stock is owned by hedge funds and other institutional investors.

About Paratek Pharmaceuticals

(Get Rating)

Paratek Pharmaceuticals, Inc engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections.

See Also

• Get a free copy of the StockNews.com research report on Paratek Pharmaceuticals (PRTK)
• This Is Why Penny Stock GreenPower Motor Company Is A Win
• Comcast Sum of All Parts is Producing a Cumulative Effect
• The Greenbrier Companies: All Aboard For High-Yield In 2023
• Coty Stock is on the Comeback Trail
• Is Halliburton Stock a Value or a Value Trap?

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.